Icosavax IPO: Seattle biotech raises $180M, stock jumps 200% on first trading day (ICVX)

Seattle biotech Icosavax surged more than 200% on its NASDAQ debut after raising over $180 million by pricing shares at $15; the company develops virus-like particle vaccines and recently began phase 1/2 trials for a COVID-19 vaccine supported by a $10 million Gates Foundation grant.

DDavid Baker IIcosavax UUniversity of Washington IInstitute for Protein Design